Cargando…

An Exploratory Dose-Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus

Atacicept, a recombinant fusion protein containing the extracellular, ligand-binding portion of the transmembrane activator and calcium modulator and cyclophilin-ligand interactor receptor, and the Fc portion of human immunoglobulin (Ig) G, is designed to block the activity of B-lymphocyte stimulato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pena-Rossi, C, Nasonov, E, Stanislav, M, Yakusevich, V, Ershova, O, Lomareva, N, Saunders, H, Hill, J, Nestorov, I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2009
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835146/ https://www.ncbi.nlm.nih.gov/pubmed/19395457 http://dx.doi.org/10.1177/0961203309102803

Ejemplares similares

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
por: Pitsiu, Maria, et al.
Publicado: (2023)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus
por: Cogollo, Estafania, et al.
Publicado: (2015)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]
Publicado: (2015)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
por: Isenberg, David, et al.
Publicado: (2015)

Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014)

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
por: Rossi, J-F, et al.
Publicado: (2009)

Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
por: Gordon, Caroline, et al.
Publicado: (2019)

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
por: Ginzler, Ellen M, et al.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017)

The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
por: Smith, Joe S., et al.
Publicado: (2023)

IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus
por: Reshetnyak, Tatiana, et al.
Publicado: (2022)

Site-specific N- and O-glycosylation analysis of atacicept
por: Stavenhagen, Kathrin, et al.
Publicado: (2019)

Kinetics of free and ligand-bound atacicept in human serum
por: Eslami, Mahya, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study
por: Zhang, Jing, et al.
Publicado: (2020)

Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
por: Reshetnyak, Tatiana, et al.
Publicado: (2023)

Intravenous Immunoglobulin in the Management of Lupus Erythematosus Panniculitis
por: AlQadri, Nada G, et al.
Publicado: (2020)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs
por: Seo, Do‐Hyun, et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double‐blind Phase Ib study
por: Walker, Alex, et al.
Publicado: (2020)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose‐escalating trial
por: Buchtele, Nina, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies
por: Studham, Matthew, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
por: Kaegi, Celine, et al.
Publicado: (2020)

No interactions between heparin and atacicept, an antagonist of B cell survival cytokines
por: Kowalczyk‐Quintas, Christine, et al.
Publicado: (2019)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
por: Nagelschmitz, J, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

Utility of Intravenous Curcumin Nanodelivery Systems for Improving In Vivo Pharmacokinetics and Anticancer Pharmacodynamics
por: Bagheri, Mahsa, et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Comparative pharmacokinetics and pharmacodynamics of intravenous artelinate versus artesunate in uncomplicated Plasmodium coatneyi-infected rhesus monkey model
por: Teja-Isavadharm, Paktiya, et al.
Publicado: (2016)

Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
por: Isenberg, David A., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamic Effects of Flunixin after Intravenous, Intramuscular and Oral Administration to Dairy Goats
por: Königsson, K, et al.
Publicado: (2003)

Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects
por: Allen, Ann, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5ahlrsj08qf2j2l8ms40b4k5fo